Circulating tumor cells as a biomarker for monitoring: Disease progression, treatment response, and minimal residual disease. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...
Interim analysis of ibrutinib plus paclitaxel for patients with advanced urothelial carcinoma previously treated with platinum-based chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results